Dmitry Balyasny’s Vertex Pharmaceuticals VRTX Stock Holding History

Dmitry Balyasny’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Sell	2,600 -3,700	-59%	-$1.64M	﹤0.01%	2067
2026 Q1	$2.81M	Sell	6,300 -800	-11%	-$373K	﹤0.01%	1626
2025 Q4	$3.22M	Buy	+7,100	New	+$3.06M	﹤0.01%	1631
2025 Q3	–	Sell	-3,600	Closed	-$1.6M	–	3509
2025 Q2	$1.6M	Buy	3,600 +1,600	+80%	+$737K	﹤0.01%	1849
2025 Q1	$970K	Buy	+2,000	New	+$932K	﹤0.01%	2001
2024 Q4	–	Sell	-500	Closed	-$233K	–	3305
2024 Q3	$233K	Sell	500 -400	-44%	-$192K	﹤0.01%	2523
2024 Q2	$422K	Buy	+900	New	+$391K	﹤0.01%	2124
2024 Q1	–	Sell	-800	Closed	-$326K	–	3163
2023 Q4	$326K	Buy	+800	New	+$296K	﹤0.01%	2124
2023 Q1	–	Sell	-16,800	Closed	-$4.85M	–	3195
2022 Q4	$4.85M	Hold	16,800	–	–	0.01%	1048
2022 Q3	$4.86M	Buy	16,800 +12,900	+331%	+$3.71M	0.01%	1013
2022 Q2	$1.1M	Buy	+3,900	New	+$1.04M	﹤0.01%	1711
2019 Q4	–	Sell	-30,000	Closed	-$5.08M	–	1518
2019 Q3	$5.08M	Buy	+30,000	New	+$5.31M	0.04%	543
2019 Q2	–	Sell	-81,000	Closed	-$14.9M	–	1750
2019 Q1	$14.9M	Buy	+81,000	New	+$15M	0.1%	291

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dmitry Balyasny's VRTX Position: Q2 2026 in Review

Dmitry Balyasny increased its Vertex Pharmaceuticals (VRTX) stake by 261% in Q2 2026, buying an estimated $46.5M and bringing the position to 145,005 shares worth $72M. The position accounts for 0.09% of the portfolio, ranked #267.

Dmitry Balyasny first reported a position in VRTX in Q2 2013 and has held it in 33 quarters since. The position peaked at $78.6M in Q1 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Dmitry Balyasny held 145,005 shares of Vertex Pharmaceuticals worth $72M as of Q2 2026.
Dmitry Balyasny bought 104,868 Vertex Pharmaceuticals shares in Q2 2026, an estimated $46.5M.
Vertex Pharmaceuticals made up 0.09% of Dmitry Balyasny's portfolio in Q2 2026, its #267 holding.
Dmitry Balyasny first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
Dmitry Balyasny's Vertex Pharmaceuticals position peaked at $78.6M in Q1 2024.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.